Literature DB >> 26354818

Significance of a Positive Toxoplasma Immunoglobulin M Test Result in the United States.

Reshika Dhakal1, Kiran Gajurel2, Christelle Pomares3, Jeanne Talucod4, Cynthia J Press4, Jose G Montoya5.   

Abstract

A positive Toxoplasma immunoglobulin M (IgM) result is often interpreted as a marker of an acute infection. However, IgM can persist for several years, and Toxoplasma commercial IgM diagnostic test kits can yield a number of false-positive results. For these reasons, a chronic Toxoplasma infection can be erroneously classified as an acute infection, resulting in serious adverse consequences, especially in pregnant women, leading to emotional distress and unnecessary interventions, including termination of pregnancy. Interpretation of Toxoplasma serology at a reference laboratory can help differentiate a recently acquired infection from a chronic infection. Serological test results for 451 patients with positive Toxoplasma IgM and IgG test results obtained at nonreference laboratories (NRLs) that were referred to Palo Alto Medical Foundation Toxoplasma Serology Laboratory (PAMF-TSL) to determine whether the patient was acutely or chronically infected were retrospectively reviewed. PAMF-TSL results established that of the 451 patients, 335 (74%) had a chronic infection, 100 (22%) had an acute infection, and 7 (2%) were not infected, and for 9 (2%), results were indeterminate. Positive Toxoplasma IgM and IgG test results obtained at NRLs cannot accurately distinguish between acute and chronic infections. To do so, testing at reference laboratories is required, as mandated in 1997 in a letter from the Food and Drug Administration (FDA) to clinicians and laboratories in the United States.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26354818      PMCID: PMC4609698          DOI: 10.1128/JCM.01663-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  High levels of IgM antibodies specific for Toxoplasma gondii in pregnancy 12 years after primary toxoplasma infection. Case report.

Authors:  B Bobić; D Sibalić; O Djurković-Djaković
Journal:  Gynecol Obstet Invest       Date:  1991       Impact factor: 2.031

2.  Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades.

Authors:  Jeffrey L Jones; Deanna Kruszon-Moran; Hilda N Rivera; Courtney Price; Patricia P Wilkins
Journal:  Am J Trop Med Hyg       Date:  2014-04-07       Impact factor: 2.345

Review 3.  The global burden of congenital toxoplasmosis: a systematic review.

Authors:  Paul R Torgerson; Pierpaolo Mastroiacovo
Journal:  Bull World Health Organ       Date:  2013-05-03       Impact factor: 9.408

4.  Comparison of the Vidas system and two recent fully automated assays for diagnosis and follow-up of toxoplasmosis in pregnant women and newborns.

Authors:  Jean-Benjamin Murat; Céline Dard; Hélène Fricker Hidalgo; Marie-Laure Dardé; Marie-Pierre Brenier-Pinchart; Hervé Pelloux
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

Review 5.  Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis.

Authors:  Jose G Montoya
Journal:  J Infect Dis       Date:  2002-02-15       Impact factor: 5.226

Review 6.  Epidemiology of and diagnostic strategies for toxoplasmosis.

Authors:  Florence Robert-Gangneux; Marie-Laure Dardé
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

7.  Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive Toxoplasma immunoglobulin M antibody titers.

Authors:  O Liesenfeld; J G Montoya; N J Tathineni; M Davis; B W Brown; K L Cobb; J Parsonnet; J S Remington
Journal:  Am J Obstet Gynecol       Date:  2001-01       Impact factor: 8.661

8.  Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies.

Authors:  L Gras; R E Gilbert; M Wallon; F Peyron; M Cortina-Borja
Journal:  Epidemiol Infect       Date:  2004-06       Impact factor: 2.451

9.  Survey of obstetrician-gynecologists in the United States about toxoplasmosis: 2012 update.

Authors:  Stephanie M Davis; Britta L Anderson; Jay Schulkin; Katherine Jones; Jodi Vanden Eng; Jeffrey L Jones
Journal:  Arch Gynecol Obstet       Date:  2014-09-10       Impact factor: 2.344

10.  Ocular toxoplasmosis in the United States: recent and remote infections.

Authors:  Jeffrey L Jones; Valerie Bonetti; Gary N Holland; Cindy Press; Steven R Sanislo; Rahul N Khurana; Jose G Montoya
Journal:  Clin Infect Dis       Date:  2014-10-09       Impact factor: 9.079

View more
  26 in total

1.  Interpretation of the Elecsys Toxo IgG avidity results for very low and very high index: study on 741 sera with a determined date of toxoplasmosis.

Authors:  H Fricker-Hidalgo; C L'Ollivier; C Bosson; S Imbert; S Bailly; C Dard; R Piarroux; L Paris; H Pelloux
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-19       Impact factor: 3.267

Review 2.  Immunoglobulin M for Acute Infection: True or False?

Authors:  Marie Louise Landry
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

3.  Public Health Surveillance and Reporting for Human Toxoplasmosis - Six States, 2021.

Authors:  Jayden McCall; Laura Rothfeldt; Kelly Giesbrecht; Amanda Hunt; Leah Bauck; Joni Scheftel; Rachael Birn; Bryan Buss; Betsy Schroeder; Thomas E Haupt; Rachel Klos; Anne Straily
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-07-15       Impact factor: 35.301

4.  Toxoplasma gondii Infection in the United States, 2011-2014.

Authors:  Jeffrey L Jones; Deanna Kruszon-Moran; Scott Elder; Hilda N Rivera; Cindy Press; Jose G Montoya; Geraldine M McQuillan
Journal:  Am J Trop Med Hyg       Date:  2017-12-14       Impact factor: 2.345

5.  Multiplexed Anti-Toxoplasma IgG, IgM, and IgA Assay on Plasmonic Gold Chips: towards Making Mass Screening Possible with Dye Test Precision.

Authors:  Xiaoyang Li; Christelle Pomares; Géraldine Gonfrier; Byumseok Koh; Shoujun Zhu; Ming Gong; Jose G Montoya; Hongjie Dai
Journal:  J Clin Microbiol       Date:  2016-03-23       Impact factor: 5.948

Review 6.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

Review 7.  The Role of microRNAs in the Infection by T. gondii in Humans.

Authors:  Geraldo Magela de Faria Junior; Fernando Henrique Antunes Murata; Hernan Alejandro Lorenzi; Bruno Bello Pede Castro; Letícia Carolina Paraboli Assoni; Christiane Maria Ayo; Cinara Cássia Brandão; Luiz Carlos de Mattos
Journal:  Front Cell Infect Microbiol       Date:  2021-05-14       Impact factor: 6.073

Review 8.  Descriptive Comparison of ELISAs for the Detection of Toxoplasma gondii Antibodies in Animals: A Systematic Review.

Authors:  K L D Tharaka D Liyanage; Anke Wiethoelter; Jasmin Hufschmid; Abdul Jabbar
Journal:  Pathogens       Date:  2021-05-15

9.  Toxoplasmosis Outbreak Associated With Toxoplasma gondii-Contaminated Venison-High Attack Rate, Unusual Clinical Presentation, and Atypical Genotype.

Authors:  Amy C Schumacher; Lina I Elbadawi; Traci DeSalvo; Anne Straily; Daniel Ajzenberg; David Letzer; Ellen Moldenhauer; Tammy L Handly; Dolores Hill; Marie-Laure Dardé; Christelle Pomares; Karine Passebosc-Faure; Kristine Bisgard; Carlos A Gomez; Cindy Press; Stephanie Smiley; José G Montoya; James J Kazmierczak
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 20.999

10.  Seroprevalence and Associated Risk Factors for Toxoplasma gondii Infection in Healthy Blood Donors: A Cross-Sectional Study in Sonora, Mexico.

Authors:  Cosme Alvarado-Esquivel; Antonio Rascón-Careaga; Jesús Hernández-Tinoco; María Alba Guadalupe Corella-Madueño; Luis Francisco Sánchez-Anguiano; María Lourdes Aldana-Madrid; Edgar Velasquez-Vega; Trinidad Quizán-Plata; José Luis Navarro-Henze; Joel Alberto Badell-Luzardo; José María Gastélum-Cano; Oliver Liesenfeld
Journal:  Biomed Res Int       Date:  2016-06-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.